Enanta Pharmaceuticals (ENTA) Revenue Growth (5y) (2017 - 2026)

Enanta Pharmaceuticals (ENTA) Revenue Growth (5y) (2017 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Enanta Pharmaceuticals 369.97 Mn 206.20 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -3.15%
Dec 31, 2025 -10.12%
Sep 30, 2025 -8.54%
Jun 30, 2025 -0.37%
Mar 31, 2025 -11.58%
Dec 31, 2024 -20.25%
Sep 30, 2024 -22.22%
Jun 30, 2024 -16.54%
Mar 31, 2024 -15.52%
Dec 31, 2023 -23.76%
Sep 30, 2023 -22.38%
Jun 30, 2023 -19.89%
Mar 31, 2023 -16.58%
Dec 31, 2022 -9.15%
Sep 30, 2022 -23.18%
Jun 30, 2022 21.00%
Mar 31, 2022 15.88%
Dec 31, 2021 21.56%
Sep 30, 2021 12.92%
Jun 30, 2021 9.12%